{"id":9543,"date":"2026-02-11T17:48:59","date_gmt":"2026-02-11T14:48:59","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9543"},"modified":"2026-02-11T17:48:59","modified_gmt":"2026-02-11T14:48:59","slug":"oral-pcsk9-inhibitor-enlicitide-achieves-ldl-c-reduction-comparable-to-injectable-therapies","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/oral-pcsk9-inhibitor-enlicitide-achieves-ldl-c-reduction-comparable-to-injectable-therapies\/","title":{"rendered":"Oral PCSK9 Inhibitor Enlicitide Achieves LDL-C Reduction Comparable to Injectable Therapies"},"content":{"rendered":"<div>Oral PCSK9 Inhibitor Enlicitide Achieves LDL-C Reduction Comparable to Injectable Therapies<\/div>\n<div><\/div>\n<div><span> \u2022 Enlicitide is an experimental oral PCSK9 inhibitor from Merck that achieved ~57% LDL-C reduction at 24 weeks in a large trial (~3,000 patients), including patients who were statin-intolerant or on background statin therapy.<\/span><\/div>\n<div><span> \u2022 LDL lowering was sustained at 1 year, with improvements in ApoB and Lp(a).<\/span><\/div>\n<div><span> \u2022 Well tolerated, with no excess adverse events or diabetes signal.<\/span><\/div>\n<div><span> \u2022 Represents the largest LDL-C reduction ever reported with an oral agent since statins.<\/span><\/div>\n<div><span> \u2022 The observed LDL-C reduction (~57%) is of a magnitude comparable to that reported with parenteral PCSK9 inhibitors, while cardiovascular outcomes data are still pending.<\/span><\/div>\n<div><span> \u2022 Not yet approved anywhere; cardiovascular outcomes trials are ongoing with possible approvals later in 2026.<\/span><\/div>\n<div><span> \u2022 Published in The New England Journal of Medicine (4 February 2026).<\/span><\/div>\n<div><\/div>\n<div>\ud83d\udd17<a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2511002\"> https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2511002<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Oral PCSK9 Inhibitor Enlicitide Achieves LDL-C Reduction Comparable to Injectable Therapies \u2022 Enlicitide is an experimental oral PCSK9 inhibitor from Merck that achieved ~57% LDL-C reduction at 24 weeks in a large trial (~3,000 patients), including patients who were statin-intolerant or on background statin therapy. \u2022 LDL lowering was sustained at 1 year, with improvements [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9543","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9543"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9543\/revisions"}],"predecessor-version":[{"id":9544,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9543\/revisions\/9544"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}